Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
Want to see HOWL full AI Analyst Report?
Top Page
Werewolf Therapeutics
(NASDAQ:HOWL)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.41
▼(-56.70% Downside)
Action:Downgraded
Date:05/20/26
The score is driven primarily by weak financial performance (heavy losses, collapsed revenue, and ongoing cash burn implying continued financing needs) and bearish technicals (price below key moving averages with negative MACD and very weak RSI/Stoch). Valuation does not provide support because the negative P/E reflects unprofitability and no dividend yield is available.
Positive Factors
Conditionally activated biologics platform
Werewolf's platform engineers cytokines to activate preferentially in the tumor microenvironment, a durable technical differentiator. That tumor-local activation approach can meaningfully reduce systemic toxicity, improving clinical tolerability and making the technology more attractive for long-term partnerships and co-development.
Negative Factors
Persistent negative operating and free cash flow
Consistent negative operating and free cash flow is a structural constraint: ongoing cash burn forces repeated capital raises or transactions, dilutes shareholders, and can delay development programs. Over 2–6 months this pressure limits strategic optionality and may compress R&D timelines or partnership leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Conditionally activated biologics platform
Werewolf's platform engineers cytokines to activate preferentially in the tumor microenvironment, a durable technical differentiator. That tumor-local activation approach can meaningfully reduce systemic toxicity, improving clinical tolerability and making the technology more attractive for long-term partnerships and co-development.
Read all positive factors
Werewolf Therapeutics (HOWL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.07M
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue Growth-100.00%
EPS Growth26.30%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.21
Shares Outstanding48,596,817
10 Day Avg. Volume1,746,006
30 Day Avg. Volume1,221,642
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.48
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.95
Enterprise Value/Ebitda-0.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.89
Revenue Forecast (FY)N/A
Werewolf Therapeutics Business Overview & Revenue Model
Company Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated m...
How the Company Makes Money
null...
Werewolf Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 1.89M | 19.94M | 16.40M | 0.00 |
| Gross Profit | -804.00K | -1.63M | 71.00K | 18.18M | 13.89M | 0.00 |
| EBITDA | -46.78M | -59.04M | -64.05M | -32.47M | -51.30M | -49.87M |
| Net Income | -56.27M | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M |
Balance Sheet | ||||||
| Total Assets | 58.02M | 69.40M | 126.93M | 174.83M | 160.25M | 179.25M |
| Cash, Cash Equivalents and Short-Term Investments | 46.45M | 57.95M | 111.00M | 134.34M | 129.31M | 157.53M |
| Total Debt | 37.65M | 9.44M | 37.09M | 51.92M | 14.68M | 15.66M |
| Total Liabilities | 45.82M | 44.59M | 53.54M | 63.46M | 37.91M | 26.46M |
| Stockholders Equity | 12.20M | 24.80M | 73.39M | 111.37M | 122.34M | 152.79M |
Cash Flow | ||||||
| Free Cash Flow | -51.94M | -60.29M | -56.44M | -33.38M | -44.21M | -43.37M |
| Operating Cash Flow | -51.94M | -60.29M | -56.19M | -32.61M | -40.60M | -42.88M |
| Investing Cash Flow | 0.00 | 0.00 | -254.00K | -769.00K | -3.61M | -498.00K |
| Financing Cash Flow | 6.03M | 6.03M | 13.08M | 58.43M | 15.91M | 109.43M |
Werewolf Therapeutics Technical Analysis
Negative
0.94
Price Trends
0.79
Negative
0.72
Negative
1.03
Negative
Market Momentum
-0.09
Positive
24.40
Positive
3.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOWL, the sentiment is Negative. The current price of 0.94 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.79, and below the 200-day MA of 1.03, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 24.40 is Positive, neither overbought nor oversold. The STOCH value of 3.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HOWL.
Werewolf Therapeutics Risk Analysis
Werewolf Therapeutics disclosed 87 risk factors in its most recent earnings report. Werewolf Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Werewolf Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $112.85M | -12.04 | 111.73% | ― | ― | 36.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $236.78M | -3.48 | -194.74% | ― | 160.53% | 12.32% | |
46 Neutral | $103.46M | -3.15 | -72.78% | ― | ― | 73.91% | |
44 Neutral | $28.15M | -1.15 | -136.08% | ― | -77.56% | -50.38% | |
40 Underperform | $24.07M | -0.75 | -208.23% | ― | -100.00% | 26.30% |
* Healthcare Sector Average
HOWL
Werewolf Therapeutics
0.43
-0.71
-62.46%
CRVO
CervoMed
2.89
-5.89
-67.08%
NRXP
NRX Pharmaceuticals
3.03
0.25
8.99%
KLRS
Kalaris Therapeutics
4.70
1.37
41.14%
CAMP
CAMP4 Therapeutics Corporation
4.15
1.92
86.10%
Werewolf Therapeutics Corporate Events
Business Operations and StrategyM&A Transactions
Werewolf Therapeutics Begins Strategic Alternatives Review Process
Neutral
Feb 24, 2026
On February 24, 2026, Werewolf Therapeutics announced it is exploring a full range of strategic alternatives to advance its immunotherapy platform and pipeline and to maximize stockholder value. The company has retained Piper Sandler Co. as its e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.